Debora Basile , Gerardo Rosati , Francesca Bergamo , Silvio Ken Garattini , Maria Banzi , Maria Zampino , Silvia Bozzarelli , Paolo Marchetti , Fabio Galli , Francesca Galli , Raffaella Longarini , Alberto Zaniboni , Daris Ferrari , Sabino De Placido , Luca Giovanni Frassineti , Mario Nicolini , Saverio Cinieri , Michele Priscindiaro , Pina Ziranu , Riccardo Caccialanza , Giuseppe Aprile
{"title":"体重指数对癌症II/III期患者的预后价值：TOSCA试验的事后分析","authors":"Debora Basile , Gerardo Rosati , Francesca Bergamo , Silvio Ken Garattini , Maria Banzi , Maria Zampino , Silvia Bozzarelli , Paolo Marchetti , Fabio Galli , Francesca Galli , Raffaella Longarini , Alberto Zaniboni , Daris Ferrari , Sabino De Placido , Luca Giovanni Frassineti , Mario Nicolini , Saverio Cinieri , Michele Priscindiaro , Pina Ziranu , Riccardo Caccialanza , Giuseppe Aprile","doi":"10.1016/j.clcc.2023.01.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>High body mass index (BMI) plays a key role in the development of colon cancer (CC). Our post-hoc analysis from the TOSCA trial analyzed the association between BMI and survival outcomes in terms of relapse-free survival (RFS) and overall survival (OS) in stage II/III CC patients.</p></div><div><h3>Patients and methods</h3><p>Patients enrolled in the TOSCA trial between 2007-2013 with BMI data entered the study. The prognostic impact of BMI on survival outcomes was investigated through uni- and multivariable Cox regression analyses.</p></div><div><h3>Results</h3><p>Overall, 1455 patients with stage II/III CC patients were included. The median follow-up was of 61.5 months; 16.1% of patients relapsed, 11.2% died and 19.5% patients relapsed or died. No impact of BMI on RFS was detected at univariate or multivariable analyses. By univariate analysis for OS, a significantly impact of a BMI > 30 kg/m<sup>2</sup> was reported (HR [>30 vs <25] 1.57, 95% CI 1.00-2.47, <em>p</em> = 0.049; HR [>30 vs <30] 1.55, 95% CI 1.01-2.37, <em>p</em> = 0.045). Multivariable analyses did not confirm this data. In the subgroup of stage III patients, a negative survival impact of BMI was found in univariate and multivariable models both for RFS and for OS.</p></div><div><h3>Conclusions</h3><p>In our study, obesity with BMI > 30 kg/m<sup>2</sup> was an independent prognostic factor for RFS and OS in CC patients treated with adjuvant chemotherapy, regardless of its duration (3 or 6 months). However, the prognostic impact of adiposity and body composition measurement should be considered to better classify patients with high visceral fat and refine their risk assessment.</p></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial\",\"authors\":\"Debora Basile , Gerardo Rosati , Francesca Bergamo , Silvio Ken Garattini , Maria Banzi , Maria Zampino , Silvia Bozzarelli , Paolo Marchetti , Fabio Galli , Francesca Galli , Raffaella Longarini , Alberto Zaniboni , Daris Ferrari , Sabino De Placido , Luca Giovanni Frassineti , Mario Nicolini , Saverio Cinieri , Michele Priscindiaro , Pina Ziranu , Riccardo Caccialanza , Giuseppe Aprile\",\"doi\":\"10.1016/j.clcc.2023.01.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>High body mass index (BMI) plays a key role in the development of colon cancer (CC). Our post-hoc analysis from the TOSCA trial analyzed the association between BMI and survival outcomes in terms of relapse-free survival (RFS) and overall survival (OS) in stage II/III CC patients.</p></div><div><h3>Patients and methods</h3><p>Patients enrolled in the TOSCA trial between 2007-2013 with BMI data entered the study. The prognostic impact of BMI on survival outcomes was investigated through uni- and multivariable Cox regression analyses.</p></div><div><h3>Results</h3><p>Overall, 1455 patients with stage II/III CC patients were included. The median follow-up was of 61.5 months; 16.1% of patients relapsed, 11.2% died and 19.5% patients relapsed or died. No impact of BMI on RFS was detected at univariate or multivariable analyses. By univariate analysis for OS, a significantly impact of a BMI > 30 kg/m<sup>2</sup> was reported (HR [>30 vs <25] 1.57, 95% CI 1.00-2.47, <em>p</em> = 0.049; HR [>30 vs <30] 1.55, 95% CI 1.01-2.37, <em>p</em> = 0.045). Multivariable analyses did not confirm this data. In the subgroup of stage III patients, a negative survival impact of BMI was found in univariate and multivariable models both for RFS and for OS.</p></div><div><h3>Conclusions</h3><p>In our study, obesity with BMI > 30 kg/m<sup>2</sup> was an independent prognostic factor for RFS and OS in CC patients treated with adjuvant chemotherapy, regardless of its duration (3 or 6 months). However, the prognostic impact of adiposity and body composition measurement should be considered to better classify patients with high visceral fat and refine their risk assessment.</p></div>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1533002823000051\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1533002823000051","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial
Background
High body mass index (BMI) plays a key role in the development of colon cancer (CC). Our post-hoc analysis from the TOSCA trial analyzed the association between BMI and survival outcomes in terms of relapse-free survival (RFS) and overall survival (OS) in stage II/III CC patients.
Patients and methods
Patients enrolled in the TOSCA trial between 2007-2013 with BMI data entered the study. The prognostic impact of BMI on survival outcomes was investigated through uni- and multivariable Cox regression analyses.
Results
Overall, 1455 patients with stage II/III CC patients were included. The median follow-up was of 61.5 months; 16.1% of patients relapsed, 11.2% died and 19.5% patients relapsed or died. No impact of BMI on RFS was detected at univariate or multivariable analyses. By univariate analysis for OS, a significantly impact of a BMI > 30 kg/m2 was reported (HR [>30 vs <25] 1.57, 95% CI 1.00-2.47, p = 0.049; HR [>30 vs <30] 1.55, 95% CI 1.01-2.37, p = 0.045). Multivariable analyses did not confirm this data. In the subgroup of stage III patients, a negative survival impact of BMI was found in univariate and multivariable models both for RFS and for OS.
Conclusions
In our study, obesity with BMI > 30 kg/m2 was an independent prognostic factor for RFS and OS in CC patients treated with adjuvant chemotherapy, regardless of its duration (3 or 6 months). However, the prognostic impact of adiposity and body composition measurement should be considered to better classify patients with high visceral fat and refine their risk assessment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
